Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF

Gołąb, Jakub; Wilczyński, Grzegorz M.; Zagożdżon, Radosław; Stokłosa, Tomasz; Dąbrowska, Anna; Rybczyńska, Jolanta; Wasik, M; Machaj, Eugeniusz K; Ołdak, Tomasz; Kozar, Katarzyna; Kaminski, Rafal; Giermasz, Adam; Czajka, Anna; Lasek, Witold; Feleszko, Wojciech; Jakóbisiak, Marek

doi:10.1054/bjoc.1999.1078

Cited by 50 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, immunisation with peptides from tumour antigens improved survival after Bremachlorin-PDT of aggressive mouse cancer models, and led to eradication of distal metastases and protection to tumour rechallenge (Kleinovink et al 2016). Similar results were found in mouse models of colon and lung carcinoma when Photofrin ® was combined with a granulocyte colony-stimulating factor (G-CSF), which stimulated innate immunity and antigen presentation (Goląb et al 2000). Combining PDT with low-dose chemotherapy led to a decrease in suppressor CD4 T cells and cured 70% of a mouse metastatic sarcoma model (Castano et al 2008).…”

Section: Combination Strategies In Pdtmentioning

confidence: 68%

Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents

2017

View full text Add to dashboard Cite

Photodynamic therapy (PDT) combines a photosensitiser, light and molecular oxygen to induce oxidative stress that can be used to kill pathogens, cancer cells and other highly proliferative cells. There is a growing number of clinically approved photosensitisers and applications of PDT, whose main advantages include the possibility of selective targeting, localised action and stimulation of the immune responses. Further improvements and broader use of PDT could be accomplished by designing new photosensitisers with increased selectivity and bioavailability. Porphyrin-based photosensitisers with amphiphilic properties, bearing one or more positive charges, are an effective tool in PDT against cancers, microbial infections and, most recently, autoimmune skin disorders. The aim of the review is to present some of the recent examples of the applications and research that employ this specific group of photosensitisers. Furthermore, we will highlight the link between their structural characteristics and PDT efficiency, which will be helpful as guidelines for rational design and evaluation of new PSs.

show abstract

Section: Combination Strategies In Pdtmentioning

confidence: 68%

Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents

2017

View full text Add to dashboard Cite

show abstract

“…Localized tumour treatment with GCSF in combination with Photofrin-mediated PDT resulted in a significant reduction of tumour growth and an increase in the length of survival of BALB/c mice bearing two types of tumour: colo 26 tumours and Lewis lung carcinomas 119 (FIG. 4).…”

Section: Pdt and Cytokine Therapymentioning

confidence: 99%

Photodynamic therapy and anti-tumour immunity

2006

View full text Add to dashboard Cite

Photodynamic therapy (PDT) uses non-toxic photosensitizers and harmless visible light in combination with oxygen to produce cytotoxic reactive oxygen species that kill malignant cells by apoptosis and/or necrosis, shut down the tumour microvasculature and stimulate the host immune system. In contrast to surgery, radiotherapy and chemotherapy that are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, invasion and infiltration of the tumour by leukocytes, and might increase the presentation of tumour-derived antigens to T cells.The principle of photodynamic therapy (PDT) was first proposed over 100 years ago 1 . A recent review in Nature Reviews Cancer by Rakesh Jain and colleagues described some of the historical milestones in the development of PDT as a cancer treatment2. Many of the photosensitizers (PSs) that have been studied since PDT was first proposed are based on a porphyrin-like nucleus 3 . PSs function as catalysts when they absorb visible light and then convert molecular oxygen to a range of highly reactive oxygen species (ROS). The ROS that are produced during PDT have been shown to destroy tumours by multifactorial mechanisms4 , 5 (FIG. 1). PDT has a direct affect on cancer cells, producing cell death by necrosis and/or apoptosis 6 . PDT also has an affect on the tumour vasculature, whereby illumination and ROS production causes the shutdown of vessels and subsequently deprives the tumour of oxygen and nutrients 7,8 . Finally, PDT also has a significant effect on the immune system 9-11 , which can be either immunostimulatory or immunosuppressive.Most of the commonly used cancer therapies are immunosuppressive. Chemotherapy and ionizing radiation delivered at doses sufficient to destroy tumours are known to be toxic to the bone marrow, which is the source of all cells of the immune system, and neutropaenia and other forms of myelosuppression are often the dose-limiting toxicity of these therapies. However, it should be noted that low doses of either ionizing radiation12 , 13 or chemotherapy14 can have immunostimulatory effects, including the induction of heat-shock © 2006 Nature Publishing Group Correspondence to M.R.H. Hamblin@helix.mgh.harvard.edu. Competing interests statementThe authors declare no competing financial interests. DATABASES NIH Public Access Author ManuscriptNat Rev Cancer. Author manuscript; available in PMC 2010 September 6. Published in final edited form as:Nat Rev Cancer. 2006 July ; 6(7): 535-545. doi:10.1038/nrc1894. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript proteins 15 . Less well known is the fact that major surgery can also have an immunosuppressive effect that leads to a significant diminution of lymphocyte and natural killer (NK) cell function 16 . The ideal cancer therapy would not only destroy the primary tumour, but at the same time trigger the immune system to recognize, track down and destroy any remaining tumour cells, be they at or near the site of the primary tumour or distant microm...

show abstract

“…During light treatment mice were anesthetized with ketamine (87 mg/kg) and xylazine (13 mg/kg) and restrained in a specially designed holder. Local tumor growth was determined as described (27) …”

Section: -Meoe 2 Potentiates Antitumor Effects Of Pdtmentioning

confidence: 99%